Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Bayer AG. (7/21/17). "Press Release: Bayer’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation [...] [Not intended for U.S. and UK Media]". Berlin.

Region Region EU (European Union)
Organisations Organisation Bayer AG
  Group Bayer (Group)
  Organisation 2 CHMP (Committee for Medicinal Products for Human Use) (EU)
  Group EU (govt)
Products Product Xarelto®
  Product 2 stent
Person Person Devoy, Michael (Bayer 201707 CMO + Head of Medical Affairs + Pharmacovigilance at Bayer Pharma)
     


   
Record changed: 2017-07-26

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top